Status:

TERMINATED

Metabolic Modulation as Treatment in Acute Heart Failure

Lead Sponsor:

University of Aarhus

Conditions:

Acute Heart Failure

Eligibility:

All Genders

18-85 years

Phase:

PHASE2

Brief Summary

The primary objective of this study is to evaluate whether metabolic modulation improves hemodynamics and outcome in acute heart failure

Detailed Description

Acute heart failure is a serious disease that despite modern therapies carries a high mortality. Inotropic drugs improve patient status but yield a higher risk of death. Previous studies have shown th...

Eligibility Criteria

Inclusion

  • Acute heart failure
  • NYHA class III - IV.
  • ejection fraction \<35

Exclusion

  • Age \<18 år or \>85 år,
  • allergy
  • renal failure
  • recently developed brady- or tachy-arrythmias
  • Serious infection
  • Heart failure due to restrictive or hypertrophic cardiomyopathy or stenotic valvular heart disease
  • Recent Myocardial infarction (\<6 Weeks)
  • Pulmonary Wedge pressure \>30 mm Hg
  • diabetes mellitus treated with insulin
  • peptic ulcer
  • pregnancy

Key Trial Info

Start Date :

March 1 2007

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

October 1 2007

Estimated Enrollment :

32 Patients enrolled

Trial Details

Trial ID

NCT00449423

Start Date

March 1 2007

End Date

October 1 2007

Last Update

October 25 2007

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Aarhus University Hospital, Skejby Sygehus, Department of Cardiology

Aarhus, Aarhus, Denmark, 8200

Metabolic Modulation as Treatment in Acute Heart Failure | DecenTrialz